EMINENT Services Expands Facilities and Strengthens European Operations

• EMINENT Services Corporation announces facility upgrades, including ISO-Class 7 clean rooms and expanded packaging capabilities.

• A new pharmaceutical packaging and storage facility in the Netherlands will begin operations in Q2 2025.

EMINENT Services Corporation, a subsidiary of EMINENT Life Sciences, has announced a significant expansion of its pharmaceutical manufacturing and clinical trial support facilities. This investment includes the introduction of ISO-Class 7 clean rooms with ISO-Class 5 sterile fill/finish capabilities, enhanced manufacturing suites, and upgraded packaging and labeling rooms. These improvements align with current good manufacturing practices (cGMP) to ensure product safety and regulatory compliance.

As part of its global growth strategy, EMINENT Services is establishing a new purpose-built facility in the Netherlands, set to become operational in Q2 2025. The facility will focus on advanced pharmaceutical packaging, offering large-scale temperature-controlled storage and streamlined solutions for injectable and oral solid dose (OSD) drug products. This expansion aims to enhance supply chain efficiency for European clients.

“Our expanded facilities represent a significant leap forward in our ability to provide end-to-end solutions for investigational drug manufacturing and pharmaceutical projects,” said Anbu S. Devasahayam, President of EMINENT Services Corporation. “This investment underscores our commitment to excellence and innovation in every aspect of our operations.”

Beyond manufacturing, the company also provides logistics, warehousing, biorepository services, and central laboratory support. Through its subsidiary, CIAN Diagnostics, EMINENT Life Sciences offers high-throughput diagnostics for genetic and infectious diseases. CEO Sam Mullapudi highlighted the company’s dedication to helping researchers manage costs while achieving clinical objectives.